> 首页 > 产品 > 一抗 > 其他 > Anti-CD3e & DLL3 & Serum Albumin Reference Antibody (Hpn328)

Anti-CD3e & DLL3 & Serum Albumin Reference Antibody (Hpn328)

Anti-CD3e & DLL3 & Serum Albumin Reference Antibody (Hpn328) on SDS-PAGE under reducing (R) condition. The purity of the protein is greater than 95%.
The purity of Anti-CD3e & DLL3 & Serum Albumin Reference Antibody (Hpn328) is 98.26%, determined by SEC-HPLC.
Hpn328 bound to DLL3 protein, and then rebounded to secondary antibodies(Anti-Human-IgG-His-HRP) , and read OD450. As shown in fig, Imm0306 bound human DLL3 Protein-Fc, and the EC50 was 0.01048 nM.
Hpn328 bound to HSA protein, and then rebounded to secondary antibodies(Anti-Human-IgG-His-HRP) , and read OD450. As shown in fig, Hpn328 bound human HSA Protein-Fc, and the EC50 was 0.06123 nM.
Co-incubation of Hpn328 with Jurkat cells, then with the addition of hu-DLL3-HEK293 cells for 6 hours. Bright-Lite was used to detect the fluorescent signal. As shown in fig, Hpn328 was able to activate the NF-AT signaling pathway.
The detected molecular weight of Anti-CD3e & DLL3 & Serum Albumin Reference Antibody (Hpn328) is 53.05 kDa.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	Functional assay, Kinetics (SPR), Kinetics (BLI), FACS, E, FTA
Primary Accession	P07766 & Q9NYJ7 & P02768
Reactivity	Human
Clonality	Bispecific
Isotype	BiTE

Additional Information
Target/Specificity	DLL3,CD3e,Serum Albumin / SA / HSA
Expression system	CHO

For Research Use Only. Not For Use In Diagnostic Procedures.

Patent Notice: The variable region sequence of this antibody is derived from a published third-party patent. This product is manufactured independently as a Research Use Only (RUO) reagent and is not licensed, sponsored, or endorsed by the patent holder. It is intended solely for research purposes. Customers considering any commercial, diagnostic, or therapeutic use should independently evaluate freedom-to-operate with respect to relevant third-party patents.